Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year, fueled by $11 million in net sales of TONMYA, its recently approved fibromyalgia treatment. The company announced that TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills surging 207%. This growth underscores the drug's market acceptance and the company's commercial execution.
TONMYA, a sublingual tablet formulation of cyclobenzaprine, is the first new treatment for fibromyalgia in over 15 years, addressing a critical unmet need in a condition that affects millions. The company noted that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, which could further boost sales and patient access.
Beyond TONMYA, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study could pave the way for a new treatment option in MDD, a condition with significant unmet need. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This initiative addresses a growing public health concern, as Lyme disease cases continue to rise in the U.S.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides Tonix with the stability to pursue its development programs and commercial expansion.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The strong sales performance of TONMYA and the company's promising pipeline highlight its potential to make a significant impact in the treatment of fibromyalgia and other CNS disorders. As coverage expands and clinical trials progress, Tonix could become a key player in addressing conditions that have long been underserved by existing therapies. Investors and patients alike will be watching closely as the company continues to execute on its commercial and clinical goals. For more information, visit the company's newsroom at https://nnw.fm/TNXP.
This news matters because it demonstrates the commercial viability of TONMYA and provides hope for fibromyalgia patients who have had limited treatment options. The company's pipeline, including potential treatments for depression and Lyme disease, could address significant public health needs. With a solid financial position, Tonix is well-positioned to advance these programs and potentially bring new therapies to market.
